Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether topotecan plus apatinib are superior to
topotecan alone as second-line therapy in small-cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
First Hospitals affiliated to the China PLA General Hospital